نتایج جستجو برای: certolizumab pegol

تعداد نتایج: 885  

2016
Benjamin Chastek John White Damon Van Voorhis Derek Tang Bradley S. Stolshek

INTRODUCTION Biologic therapies are used to treat several inflammatory diseases, including rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Data from a commercial claims database were used to evaluate utilization and cost of biologic treatment for these conditions. METHODS Data were obtained from the Optum Research Database. Patients were...

2012
Kacper A. Wojtal Gerhard Rogler Michael Scharl Luc Biedermann Pascal Frei Michael Fried Achim Weber Jyrki J. Eloranta Gerd A. Kullak-Ublick Stephan R. Vavricka

BACKGROUND Tumor necrosis factor (TNF) is an important cytokine in the pathogenesis of inflammatory bowel disease (IBD). Anti-TNF antibodies have been successfully implemented in IBD therapy, however their efficacies differ among IBD patients. Here we investigate the influence of CD64 Fc receptor on the inhibitory activity of anti-TNFs in cells of intestinal wall. METHODS Intestinal cell line...

2017
D. van der Heijde A. Deodhar R. Fleischmann P. J. Mease M. Rudwaleit T. Nurminen O. Davies

OBJECTIVE Early identification of patients unlikely to achieve good long-term disease control with anti-tumor necrosis factor therapy in axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) is important for physicians following treat-to-target recommendations. Here we assess associations between disease activity or clinical response during the first 12 weeks of treatment and attainment o...

Journal: :The Journal of rheumatology 2011
Robert Launois Bernard Avouac Francis Berenbaum Olivier Blin Isabelle Bru Bruno Fautrel Jean-Michel Joubert Jean Sibilia Bernard Combe

OBJECTIVE To compare the clinical efficacy of certolizumab pegol (CZP) with that of other anticytokine agents indicated for the treatment of rheumatoid arthritis (RA) with identical therapeutic indication (anti-tumor necrosis factor-α, anti-interleukin 1 or 6), with the objective of determining the noninferiority of CZP. METHODS A systematic review was performed to identify randomized control...

Journal: :The Journal of rheumatology 2015
Megan E B Clowse Douglas C Wolf Frauke Förger John J Cush Amanda Golembesky Laura Shaughnessy Dirk De Cuyper Uma Mahadevan

OBJECTIVE To provide information on pregnancy outcomes in women receiving certolizumab pegol (CZP). METHODS The UCB Pharma safety database was searched for pregnancies through to September 1, 2014. Reports for maternal and paternal CZP exposure were included and outcomes examined, and data on CZP exposure, pregnancy, comorbidities, and infant events were extracted by 2 independent reviewers. ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید